Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| Total number of shares and voting rights in Zealand Pharma at March 31, 2019 | 29 Mar 2019 |
| Zealand Pharma announces completion of the share subscription by Alexion Pharmaceuticals, Inc. and registration of capital increase | 21 Mar 2019 |
| Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases | 20 Mar 2019 |
| Zealand Pharma increases its share capital as a consequence of a new issue of shares | 20 Mar 2019 |
| Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | 15 Mar 2019 |